- Rhone-Poulenc Rorer has submitted New Drug Applications toregulatory authorities in the USA and Europe for its combination estrogen/progestogen patch. The US application seeks approval for the relief of moderate-to-severe vasomotor symptoms associated with menopause, while the European application seeks additional approval for the prevention of post-menopausal osteoporosis. In a separate statement, R-PR says it has received clearance to market its recombinant human granulocyte colony-stimulating factor product Granocyte (lenograstim) in 14 more countries, bringing the total to 41.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze